Selection of molecular targets for drug development against trypanosomatids

Sub-Cellular Biochemistry

Volumn 74, Issue , 2014, Pages 43-76

  Smirlis, Despina ^a   Soares, Milena Botelho Pereira ^b,c  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c HOSPITAL SÃO RAFAEL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIA; PROTOZOA; TRYPANOSOMA; TRYPANOSOMATIDAE;

ANTITRYPANOSOMAL AGENT;

ANIMAL; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; REVIEW; TRYPANOSOMA;

ANIMALS; DRUG DESIGN; TRYPANOCIDAL AGENTS; TRYPANOSOMA;

EID: 84901733751     PISSN: 03060225     EISSN: None     Source Type: Journal    
DOI: 10.1007/978-94-007-7305-9_2     Document Type: Article

References (187)

1. Abdulla MH, O’Brien T, Mackey ZB, Sajid M, Grab DJ, McKerrow JH (2008) RNA interference of Trypanosoma brucei cathepsin B and L affects disease progression in a mouse model. PLoS Negl Trop Dis 2:e298
2. Al-Abdely HM, Graybill JR, Loebenberg D, Melby PC (1999) Effi cacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases. Antimicrob Agents Chemother 43:2910–2914
3. Alexander J, Coombs GH, Mottram JC (1998) Leishmania mexicana cysteine proteinase-defi cient mutants have attenuated virulence for mice and potentiate a Th1 response. J Immunol 161:6794–6801
4. Alves-Ferreira M, Guimaraes AC, Capriles PV, Dardenne LE, Degrave WM (2009) A new approach for potential drug target discovery through in silico metabolic pathway analysis using Trypanosoma cruzi genome information. Mem Inst Oswaldo Cruz 104:1100–1110
5. Ambit A, Fasel N, Coombs GH, Mottram JC (2008) An essential role for the Leishmania major metacaspase in cell cycle progression. Cell Death Differ 15:113–122
6. Arsenieva D, Appavu BL, Mazock GH, Jeffery CJ (2009) Crystal structure of phosphoglucose isomerase from Trypanosoma brucei complexed with glucose-6-phosphate at 1.6 A resolution. Proteins 74:72–80
7. Aslett M, Aurrecoechea C, Berriman M, Brestelli J, Brunk BP, Carrington M, Depledge DP, Fischer S, Gajria B, Gao X, Gardner MJ, Gingle A, Grant G, Harb OS, Heiges M, Hertz-Fowler C, Houston R, Innamorato F, Iodice J, Kissinger JC, Kraemer E, Li W, Logan FJ, Miller JA, Mitra S, Myler PJ, Nayak V, Pennington C, Phan I, Pinney DF, Ramasamy G, Rogers MB, Roos DS, Ross C, Sivam D, Smith DF, Srinivasamoorthy G, Stoeckert CJ Jr, Subramanian S, Thibodeau R, Tivey A, Treatman C, Velarde G, Wang H (2010) TriTrypDB: a functional genomic resource for the Trypanosomatidae. Nucleic Acids Res 38:D457–462
8. Bakshi RP, Shapiro TA (2004) RNA interference of Trypanosoma brucei topoisomerase IB: both subunits are essential. Mol Biochem Parasitol 136:249–255
9. Balana-Fouce R, Redondo CM, Perez-Pertejo Y, Diaz-Gonzalez R, Reguera RM (2006) Targeting atypical trypanosomatid DNA topoisomerase I. Drug Discov Today 11:733–740
10. Banerjee S, Sen A, Das P, Saha P (2006) Leishmania donovani cyclin 1 (LdCyc1) forms a complex with cell cycle kinase subunit CRK3 (LdCRK3) and is possibly involved in S-phase-related activities. FEMS Microbiol Lett 256:75–82
11. Barr SC, Warner KL, Kornreic BG, Piscitelli J, Wolfe A, Benet L, McKerrow JH (2005) A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob Agents Chemother 49:5160–5161
12. Beck JT, Ullman B (1990) Nutritional requirements of wild-type and folate transport-defi cient Leishmania donovani for pterins and folates. Mol Biochem Parasitol 43:221–230
13. Bengs F, Scholz A, Kuhn D, Wiese M (2005) LmxMPK9, a mitogen-activated protein kinase homologue affects fl agellar length in Leishmania mexicana. Mol Microbiol 55:1606–1615
14. Bernstein BE, Michels PA, Hol WG (1997) Synergistic effects of substrate-induced conforma-tional changes in phosphoglycerate kinase activation. Nature 385:275–278
15. Bernstein BE, Michels PA, Kim H, Petra PH, Hol WG (1998) The importance of dynamic light scattering in obtaining multiple crystal forms of Trypanosoma brucei PGK. Protein Sci 7:504–507
16. Berriman M, Ghedin E, Hertz-Fowler C, Blandin G, Renauld H, Bartholomeu DC, Lennard NJ, Caler E, Hamlin NE, Haas B, Bohme U, Hannick L, Aslett MA, Shallom J, Marcello L, Hou L, Wickstead B, Alsmark UC, Arrowsmith C, Atkin RJ, Barron AJ, Bringaud F, Brooks K, Carrington M, Cherevach I, Chillingworth TJ, Churcher C, Clark LN, Corton CH, Cronin A, Davies RM, Doggett J, Djikeng A, Feldblyum T, Field MC, Fraser A, Goodhead I, Hance Z, Harper D, Harris BR, Hauser H, Hostetler J, Ivens A, Jagels K, Johnson D, Johnson J, Jones K, Kerhornou AX, Koo H, Larke N, Landfear S, Larkin C, Leech V, Line A, Lord A, Macleod A, Mooney PJ, Moule S, Martin DM, Morgan GW, Mungall K, Norbertczak H, Ormond D, Pai G, Peacock CS, Peterson J, Quail MA, Rabbinowitsch E, Rajandream MA, Reitter C, Salzberg SL, Sanders M, Schobel S, Sharp S, Simmonds M, Simpson AJ, Tallon L, Turner CM, Tait A, Tivey AR, Van Aken S, Walker D, Wanless D, Wang S, White B, White O, Whitehead S, Woodward J, Wortman J, Adams MD, Embley TM, Gull K, Ullu E, Barry JD, Fairlamb AH, Opperdoes F, Barrell BG, Donelson JE, Hall N, Fraser CM, Melville SE, El-Sayed NM (2005) The genome of the African trypanosome Trypanosoma brucei. Science 309:416–422
17. Bodley AL, Wani MC, Wall ME, Shapiro TA (1995) Antitrypanosomal activity of camptothecin analogs. Structure-activity correlations. Biochem Pharmacol 50:937–942
18. Boitz JM, Ullman B, Jardim A, Carter NS (2012) Purine salvage in Leishmania: complex or simple by design? Trends Parasitol 28:345–352
19. Boukai LK, da Costa-Pinto D, Soares MJ, McMahon-Pratt D, Traub-Cseko YM (2000) Traffi cking of cysteine proteinase to Leishmania lysosomes: lack of involvement of glycosylation. Mol Biochem Parasitol 107:321–325
20. Brak K, Doyle PS, McKerrow JH, Ellman JA (2008) Identifi cation of a new class of nonpeptidic inhibitors of cruzain. J Am Chem Soc 130:6404–6410
21. Bryson K, Besteiro S, McGachy HA, Coombs GH, Mottram JC, Alexander J (2009) Overexpression of the natural inhibitor of cysteine peptidases in Leishmania mexicana leads to reduced virulence and a Th1 response. Infect Immun 77:2971–2978
22. Buckner FS, Griffi n JH, Wilson AJ, Van Voorhis WC (2001) Potent anti- Trypanosoma cruzi activities of oxidosqualene cyclase inhibitors. Antimicrob Agents Chemother 45:1210–1215
23. Buckner FS, Nguyen LN, Joubert BM, Matsuda SP (2000) Cloning and heterologous expression of the Trypanosoma brucei lanosterol synthase gene. Mol Biochem Parasitol 110:399–403
24. Burri C, Brun R (2003) Efl ornithine for the treatment of human African trypanosomiasis. Parasitol Res 90(Supp 1):S49–52
25. Caceres AJ, Portillo R, Acosta H, Rosales D, Quinones W, Avilan L, Salazar L, Dubourdieu M, Michels PA, Concepcion JL (2003) Molecular and biochemical characterization of hexokinase from Trypanosoma cruzi. Mol Biochem Parasitol 126:251–262
26. Caffrey CR, Scory S, Steverding D (2000) Cysteine proteinases of trypanosome parasites: novel targets for chemotherapy. Curr Drug Targets 1:155–162
27. Castro JA, Diaz de Toranzo EG (1988) Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas’ disease). Biomed Environ Sci 1:19–33
28. Cazzulo JJ (2002) Proteinases of Trypanosoma cruzi: potential targets for the chemotherapy of Chagas disease. Curr Top Med Chem 2:1261–1271
29. Ceylan S, Seidel V, Ziebart N, Berndt C, Dirdjaja N, Krauth-Siegel RL (2010) The dithiol glutare-doxins of African trypanosomes have distinct roles and are closely linked to the unique trypano-thione metabolism. J Biol Chem 285:35224–35237
30. Chambers JW, Kearns MT, Morris MT, Morris JC (2008a) Assembly of heterohexameric trypanosome hexokinases reveals that hexokinase 2 is a regulable enzyme. J Biol Chem 283:14963–14970
31. Chambers JW, Fowler ML, Morris MT, Morris JC (2008b) The anti-trypanosomal agent lonidamine inhibits Trypanosoma brucei hexokinase 1. Mol Biochem Parasitol 158:202–207
32. Champoux JJ, Dulbecco R (1972) An activity from mammalian cells that untwists superhelical DNA–a possible swivel for DNA replication (polyoma-ethidium bromide-mouse-embryo cells-dye binding assay). Proc Natl Acad Sci USA 69:143–146
33. Chawla B, Madhubala R (2010) Drug targets in Leishmania. J Parasit Dis 34:1–13
34. Chudzik DM, Michels PA, de Walque S, Hol WG (2000) Structures of type 2 peroxisomal targeting signals in two trypanosomatid aldolases. J Mol Biol 300:697–707
35. Cleghorn LA, Woodland A, Collie IT, Torrie LS, Norcross N, Luksch T, Mpamhanga C, Walker RG, Mottram JC, Brenk R, Frearson JA, Gilbert IH, Wyatt PG (2011) Identifi cation of inhibitors of the Leishmania cdc2-related protein kinase CRK3. ChemMedChem 6:2214–2224
36. Coppens I, Baudhuin P, Opperdoes FR, Courtoy PJ (1988) Receptors for the host low density lipoproteins on the hemofl agellate Trypanosoma brucei: purifi cation and involvement in the growth of the parasite. Proc Natl Acad Sci USA 85:6753–6757
37. Cordeiro AT, Michels PA, Delboni LF, Thiemann OH (2004) The crystal structure of glucose-6-phosphate isomerase from Leishmania mexicana reveals novel active site features. Eur J Biochem 271:2765–2772
38. Croft SL, Sundar S, Fairlamb AH (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19:111–126
39. Crowther GJ, Shanmugam D, Carmona SJ, Doyle MA, Hertz-Fowler C, Berriman M, Nwaka S, Ralph SA, Roos DS, Van Voorhis WC, Aguero F (2010) Identifi cation of attractive drug targets in neglected-disease pathogens using an in silico approach. PLoS Negl Trop Dis 4:e804
40. Das BB, Sen N, Dasgupta SB, Ganguly A, Das R, Majumder HK (2006a) Topoisomerase research of kinetoplastid parasite Leishmania, with special reference to development of therapeutics. Indian J Med Res 123:221–232
41. Das BB, Sen N, Ganguly A, Majumder HK (2004) Reconstitution and functional characterization of the unusual bi-subunit type I DNA topoisomerase from Leishmania donovani. FEBS Lett 565:81–88
42. Das BB, Sen N, Roy A, Dasgupta SB, Ganguly A, Mohanta BC, Dinda B, Majumder HK (2006b) Differential induction of Leishmania donovani bi-subunit topoisomerase I-DNA cleavage complex by selected fl avones and camptothecin: activity of fl avones against camptothecin-resistant topoisomerase I. Nucleic Acids Res 34:1121–1132
43. Datta AK, Bhaumik D, Chatterjee R (1987) Isolation and characterization of adenosine kinase from Leishmania donovani. J Biol Chem 262:5515–5521
44. Dax C, Duffi eux F, Chabot N, Coincon M, Sygusch J, Michels PA, Blonski C (2006) Selective irreversible inhibition of fructose 1,6-bisphosphate aldolase from Trypanosoma brucei. J Med Chem 49:1499–1502
45. de AS Navarro MV, Gomes Dias SM, Mello LV, da Silva Giotto MT, Gavalda S, Blonski C, Garratt RC, Rigden DJ (2007) Structural fl exibility in Trypanosoma brucei enolase revealed by X-ray crystallography and molecular dynamics. FEBS J 274:5077–5089
46. de Koning HP, Bridges DJ, Burchmore RJ (2005) Purine and pyrimidine transport in pathogenic protozoa: from biology to therapy. FEMS Microbiol Rev 29:987–1020
47. De Koning HP (2008) Ever increasing complexities of diamidine and arsenical cross resistance in African trypanosomes. Trends Parasitol 24:345–349
48. De Sousa JM, Lareau SM, Pearson RD, Carvalho EM, Mann BJ, Jeronimo SM (2003) Characterization of Leishmania chagasi DNA topoisomerase II: a potential chemotherapeutic target. Scand J Infect Dis 35:826–829
49. de Souza W, Rodrigues JC (2009) Sterol biosynthesis pathway as target for anti-trypanosomatid drugs. Interdiscip Perspect Infect Dis 2009:642502
50. Deterding A, Dungey FA, Thompson KA, Steverding D (2005) Anti-trypanosomal activities of DNA topoisomerase inhibitors. Acta Trop 93:311–316
51. Domenicali Pfi ster D, Burkard G, Morand S, Renggli CK, Roditi I, Vassella E (2006) A mitogen-activated protein kinase controls differentiation of bloodstream forms of Trypanosoma brucei. Eukaryot Cell 5:1126–1135
52. Douc-Rasy S, Riou JF, Ahomadegbe JC, Riou G (1988) ATP-independent DNA topoisomerase II as potential drug target in trypanosomes. Biol Cell 64:145–156
53. Doyle MA, MacRae JI, De Souza DP, Saunders EC, McConville MJ, Likic VA (2009) LeishCyc: a biochemical pathways database for Leishmania major. BMC Syst Biol 3:57
54. Doyle PS, Zhou YM, Engel JC, McKerrow JH (2007) A cysteine protease inhibitor cures Chagas’ disease in an immunodefi cient-mouse model of infection. Antimicrob Agents Chemother 51:3932–3939
55. Drew ME, Morris JC, Wang Z, Wells L, Sanchez M, Landfear SM, Englund PT (2003) The ade-nosine analog tubercidin inhibits glycolysis in Trypanosoma brucei as revealed by an RNA interference library. J Biol Chem 278:46596–46600
56. Du X, Guo C, Hansell E, Doyle PS, Caffrey CR, Holler TP, McKerrow JH, Cohen FE (2002) Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J Med Chem 45:2695–2707
57. Eakin AE, Guerra A, Focia PJ, Torres-Martinez J, Craig SP (1997) Hypoxanthine phospho-ribosyltransferase from Trypanosoma cruzi as a target for structure-based inhibitor design: crystallization and inhibition studies with purine analogs. Antimicrob Agents Chemother 41:1686–1692
58. El-Sayed NM, Myler PJ, Bartholomeu DC, Nilsson D, Aggarwal G, Tran AN, Ghedin E, Worthey EA, Delcher AL, Blandin G, Westenberger SJ, Caler E, Cerqueira GC, Branche C, Haas B, Anupama A, Arner E, Aslund L, Attipoe P, Bontempi E, Bringaud F, Burton P, Cadag E, Campbell DA, Carrington M, Crabtree J, Darban H, da Silveira JF, de Jong P, Edwards K, Englund PT, Fazelina G, Feldblyum T, Ferella M, Frasch AC, Gull K, Horn D, Hou L, Huang Y, Kindlund E, Klingbeil M, Kluge S, Koo H, Lacerda D, Levin MJ, Lorenzi H, Louie T, Machado CR, McCulloch R, McKenna A, Mizuno Y, Mottram JC, Nelson S, Ochaya S, Osoegawa K, Pai G, Parsons M, Pentony M, Pettersson U, Pop M, Ramirez JL, Rinta J, Robertson L, Salzberg SL, Sanchez DO, Seyler A, Sharma R, Shetty J, Simpson AJ, Sisk E, Tammi MT, Tarleton R, Teixeira S, Van Aken S, Vogt C, Ward PN, Wickstead B, Wortman J, White O, Fraser CM, Stuart KD, Andersson B (2005a) The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 309:409–415
59. El-Sayed NM, Myler PJ, Blandin G, Berriman M, Crabtree J, Aggarwal G, Caler E, Renauld H, Worthey EA, Hertz-Fowler C, Ghedin E, Peacock C, Bartholomeu DC, Haas BJ, Tran AN, Wortman JR, Alsmark UC, Angiuoli S, Anupama A, Badger J, Bringaud F, Cadag E, Carlton JM, Cerqueira GC, Creasy T, Delcher AL, Djikeng A, Embley TM, Hauser C, Ivens AC, Kummerfeld SK, Pereira-Leal JB, Nilsson D, Peterson J, Salzberg SL, Shallom J, Silva JC, Sundaram J, Westenberger S, White O, Melville SE, Donelson JE, Andersson B, Stuart KD, Hall N (2005b) Comparative genomics of trypanosomatid parasitic protozoa. Science 309:404–409
60. Elhalem E, Bailey BN, Docampo R, Ujvary I, Szajnman SH, Rodriguez JB (2002) Design, synthesis, and biological evaluation of aryloxyethyl thiocyanate derivatives against T rypanosoma cruzi. J Med Chem 45:3984–3999
61. Ellis J, Sarkar M, Hendriks E, Matthews K (2004) A novel ERK-like, CRK-like protein kinase that modulates growth in Trypanosoma brucei via an autoregulatory C-terminal extension. Mol Microbiol 53:1487–1499
62. Engel JC, Doyle PS, Palmer J, Hsieh I, Bainton DF, McKerrow JH (1998) Cysteine protease inhibitors alter golgi complex ultrastructure and function in Trypanosoma cruzi. J Cell Sci 111(Pt 5):597–606
63. Fernandes Rodrigues JC, Concepcion JL, Rodrigues C, Caldera A, Urbina JA, de Souza W (2008) In vitro activities of ER-119884 and E5700, two potent squalene synthase inhibitors, against Leishmania amazonensis: antiproliferative, biochemical, and ultrastructural effects. Antimicrob Agents Chemother 52:4098–4114
64. Figgitt D, Denny W, Chavalitshewinkoon P, Wilairat P, Ralph R (1992) In vitro study of anticancer acridines as potential antitrypanosomal and antimalarial agents. Antimicrob Agents Chemother 36:1644–1647
65. Flohe L (2012) The trypanothione system and the opportunities it offers to create drugs for the neglected kinetoplast diseases. Biotechnol Adv 30:294–301
66. Freymann DM, Wenck MA, Engel JC, Feng J, Focia PJ, Eakin AE, Craig SP (2000) Effi cient identifi cation of inhibitors targeting the closed active site conformation of the HPRT from Trypanosoma cruzi. Chem Biol 7:957–968
67. Galvao-Quintao L, Alfi eri SC, Ryter A, Rabinovitch M (1990) Intracellular differentiation of Leishmania amazonensis promastigotes to amastigotes: presence of megasomes, cysteine proteinase activity and susceptibility to leucine-methyl ester. Parasitology 101(Pt 1):7–13
68. Goad LJ, Holz GG Jr, Beach DH (1985) Effect of the allylamine antifungal drug SF 86-327 on the growth and sterol synthesis of Leishmania mexicana mexicana promastigotes. Biochem Pharmacol 34:3785–3788
69. Gomes FC, Ali NO, Brown E, Walker RG, Grant KM, Mottram JC (2010) Recombinant Leishmania mexicana CRK3: CYCA has protein kinase activity in the absence of phosphorylation on the T-loop residue Thr178. Mol Biochem Parasitol 171:89–96
70. Grant KM, Dunion MH, Yardley V, Skaltsounis AL, Marko D, Eisenbrand G, Croft SL, Meijer L, Mottram JC (2004) Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity. Antimicrob Agents Chemother 48:3033–3042
71. Grant KM, Hassan P, Anderson JS, Mottram JC (1998) The crk3 gene of Leishmania mexicana encodes a stage-regulated cdc2-related histone H1 kinase that associates with p12. J Biol Chem 273:10153–10159
72. Guido RV, Trossini GH, Castilho MS, Oliva G, Ferreira EI, Andricopulo AD (2008) Structure-activity relationships for a class of selective inhibitors of the major cysteine protease from Trypanosoma cruzi. J Enzyme Inhib Med Chem 23:964–973
73. Ha S, Seo YJ, Kwon MS, Chang BH, Han CK, Yoon JH (2008) IDMap: facilitating the detection of potential leads with therapeutic targets. Bioinformatics 24:1413–1415
74. Hammarton TC, Clark J, Douglas F, Boshart M, Mottram JC (2003) Stage-specifi c differences in cell cycle control in Trypanosoma brucei revealed by RNA interference of a mitotic cyclin. J Biol Chem 278:22877–22886
75. Hammarton TC, Engstler M, Mottram JC (2004) The Trypanosoma brucei cyclin, CYC2, is required for cell cycle progression through G1 phase and for maintenance of procyclic form cell morphology. J Biol Chem 279:24757–24764
76. Hardy LW, Matthews W, Nare B, Beverley SM (1997) Biochemical and genetic tests for inhibitors of Leishmania pteridine pathways. Exp Parasitol 87:157–169
77. Hartsel S, Bolard J (1996) Amphotericin B: new life for an old drug. Trends Pharmacol Sci 17:445–449
78. Hassan P, Fergusson D, Grant KM, Mottram JC (2001) The CRK3 protein kinase is essential for cell cycle progression of Leishmania mexicana. Mol Biochem Parasitol 113:189–198
79. Henriksen EJ, Kinnick TR, Teachey MK, O’Keefe MP, Ring D, Johnson KW, Harrison SD (2003) Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty rats. Am J Physiol Endocrinol Metab 284:E892–900
80. Hudock MP, Sanz-Rodriguez CE, Song Y, Chan JM, Zhang Y, Odeh S, Kosztowski T, Leon- Rossell A, Concepcion JL, Yardley V, Croft SL, Urbina JA, Oldfi eld E (2006) Inhibition of Trypanosoma cruzi hexokinase by bisphosphonates. J Med Chem 49:215–223
81. Iovannisci DM, Ullman B (1984) Characterization of a mutant Leishmania donovani defi cient in adenosine kinase activity. Mol Biochem Parasitol 12:139–151
82. Ivens AC, Peacock CS, Worthey EA, Murphy L, Aggarwal G, Berriman M, Sisk E, Rajandream MA, Adlem E, Aert R, Anupama A, Apostolou Z, Attipoe P, Bason N, Bauser C, Beck A, Beverley SM, Bianchettin G, Borzym K, Bothe G, Bruschi CV, Collins M, Cadag E, Ciarloni L, Clayton C, Coulson RM, Cronin A, Cruz AK, Davies RM, De Gaudenzi J, Dobson DE, Duesterhoeft A, Fazelina G, Fosker N, Frasch AC, Fraser A, Fuchs M, Gabel C, Goble A, Goffeau A, Harris D, Hertz-Fowler C, Hilbert H, Horn D, Huang Y, Klages S, Knights A, Kube M, Larke N, Litvin L, Lord A, Louie T, Marra M, Masuy D, Matthews K, Michaeli S, Mottram JC, Muller-Auer S, Munden H, Nelson S, Norbertczak H, Oliver K, O’Neil S, Pentony M, Pohl TM, Price C, Purnelle B, Quail MA, Rabbinowitsch E, Reinhardt R, Rieger M, Rinta J, Robben J, Robertson L, Ruiz JC, Rutter S, Saunders D, Schafer M, Schein J, Schwartz DC, Seeger K, Seyler A, Sharp S, Shin H, Sivam D, Squares R, Squares S, Tosato V, Vogt C, Volckaert G, Wambutt R, Warren T, Wedler H, Woodward J, Zhou S, Zimmermann W, Smith DF, Blackwell JM, Stuart KD, Barrell B, Myler PJ (2005) The genome of the kinetoplastid parasite, Leishmania major. Science 309:436–442
83. John von Freyend S, Rosenqvist H, Fink A, Melzer IM, Clos J, Jensen ON, Wiese M (2010) LmxMPK4, an essential mitogen-activated protein kinase of Leishmania mexicana is phosphorylated and activated by the STE7-like protein kinase LmxMKK5. Int J Parasitol 40:969–978
84. Kager PA, Rees PH, Wellde BT, Hockmeyer WT, Lyerly WH (1981) Allopurinol in the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 75:556–559
85. Kaidanovich-Beilin O, Eldar-Finkelman H (2006) Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle. J Pharmacol Exp Ther 316:17–24
86. Khan MO (2007) Trypanothione reductase: a viable chemotherapeutic target for antitrypanosomal and antileishmanial drug design. Drug Target Insights 2:129–146
87. Kim H, Feil IK, Verlinde CL, Petra PH, Hol WG (1995) Crystal structure of glycosomal glyceraldehyde- 3-phosphate dehydrogenase from Leishmania mexicana: implications for structure-based drug design and a new position for the inorganic phosphate binding site. Biochemistry 34:14975–14986
88. Krauth-Siegel RL, Comini MA (2008) Redox control in trypanosomatids, parasitic protozoa with trypanothione-based thiol metabolism. Biochim Biophys Acta 1780:1236–1248
89. Krieger S, Schwarz W, Ariyanayagam MR, Fairlamb AH, Krauth-Siegel RL, Clayton C (2000) Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress. Mol Microbiol 35:542–552
90. LaFon SW, Nelson DJ, Berens RL, Marr JJ (1982) Purine and pyrimidine salvage pathways in Leishmania donovani. Biochem Pharmacol 31:231–238
91. Lakhdar-Ghazal F, Blonski C, Willson M, Michels P, Perie J (2002) Glycolysis and proteases as targets for the design of new anti-trypanosome drugs. Curr Top Med Chem 2:439–56
92. Legros D, Ollivier G, Gastellu-Etchegorry M, Paquet C, Burri C, Jannin J, Buscher P (2002) Treatment of human African trypanosomiasis–present situation and needs for research and development. Lancet Infect Dis 2:437–440
93. Leon LL, Temporal RM, Soares MJ, Grimaldi Junior G (1994) Proteinase activities during temperature- induced stage differentiation of species complexes of Leishmania. Acta Trop 56:289–298
94. Li Z, Wang CC (2003) A PHO80-like cyclin and a B-type cyclin control the cell cycle of the procyclic form of Trypanosoma brucei. J Biol Chem 278:20652–20658
95. Looker DL, Berens RL, Marr JJ (1983) Purine metabolism in Leishmania donovani amastigotes and promastigotes. Mol Biochem Parasitol 9:15–28
96. Lorente SO, Rodrigues JC, Jimenez Jimenez C, Joyce-Menekse M, Rodrigues C, Croft SL, Yardley V, de Luca-Fradley K, Ruiz-Perez LM, Urbina J, de Souza W, Gonzalez Pacanowska D, Gilbert IH (2004) Novel azasterols as potential agents for treatment of leishmaniasis and trypanoso-miasis. Antimicrob Agents Chemother 48:2937–2950
97. Luscher A, Onal P, Schweingruber AM, Maser P (2007) Adenosine kinase of Trypanosoma brucei and its role in susceptibility to adenosine antimetabolites. Antimicrob Agents Chemother 51:3895–3901
98. Magaraci F, Jimenez CJ, Rodrigues C, Rodrigues JC, Braga M V, Yardley V, de Luca-Fradley K, Croft SL, de Souza W, Ruiz-Perez LM, Urbina J, Gonzalez Pacanowska D, Gilbert IH (2003) Azasterols as inhibitors of sterol 24-methyltransferase in Leishmania species and Trypanosoma cruzi. J Med Chem 46:4714–4727
99. Maldonado E, Soriano-Garcia M, Moreno A, Cabrera N, Garza-Ramos G, de Gomez-Puyou M, Gomez-Puyou A, Perez-Montfort R (1998) Differences in the intersubunit contacts in triosephos-phate isomerase from two closely related pathogenic trypanosomes. J Mol Biol 283:193–203
100. Mallari JP, Shelat AA, Kosinski A, Caffrey CR, Connelly M, Zhu F, McKerrow JH, Guy RK (2009) Structure-guided development of selective TbcatB inhibitors. J Med Chem 52:6489–6493
101. Mallari JP, Zhu F, Lemoff A, Kaiser M, Lu M, Brun R, Guy RK (2010) Optimization of purine-nitrile TbcatB inhibitors for use in vivo and evaluation of effi cacy in murine models. Bioorg Med Chem 18:8302–8309
102. Marr JJ, Berens RL (1983) Pyrazolopyrimidine metabolism in the pathogenic trypanosomatidae. Mol Biochem Parasitol 7:339–356
103. Marr JJ, Berens RL, Nelson DJ (1978) Purine metabolism in Leishmania donovani and Leishmania braziliensis. Biochim Biophys Acta 544:360–371
104. Marshall WF, Rosenbaum JL (2001) Intrafl agellar transport balances continuous turnover of outer doublet microtubules: implications for fl agellar length control. J Cell Biol 155:405–414
105. Martinez-Oyanedel J, McNae IW, Nowicki MW, Keillor JW, Michels PA, Fothergill-Gilmore LA, Walkinshaw MD (2007) The fi rst crystal structure of phosphofructokinase from a eukaryote: Trypanosoma brucei. J Mol Biol 366:1185–1198
106. Martinez S, Marr JJ (1992) Allopurinol in the treatment of American cutaneous leishmaniasis.N Engl J Med 326:741–744
107. McNae IW, Martinez-Oyanedel J, Keillor JW, Michels PA, Fothergill-Gilmore LA, Walkinshaw MD (2009) The crystal structure of ATP-bound phosphofructokinase from rypanosoma brucei reveals conformational transitions different from those of other phosphofructokinases.J Mol Biol 385:1519–1533
108. Molina J, Martins-Filho OA, Brener Z, Romanha AJ, Loebenberg D, Urbina JA (2000) Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immuno-suppressed murine hosts. Antimicrob Agents Ch 44:150–155
109. Monzani PS, Trapani S, Thiemann OH, Oliva G (2007) Crystal structure of Leishmania tarentolaehypoxanthine-guanine phosphoribosyltransferase. BMC Struct Biol 7:59
110. Morales MA, Renaud O, Faigle W, Shorte SL, Spath GF (2007) Over-expression of Leishmania major MAP kinases reveals stage-specifi c induction of phosphotransferase activity. Int J Parasitol37:1187–1199
111. Moreira W, Leblanc E, Ouellette M (2009) The role of reduced pterins in resistance to reactive oxygen and nitrogen intermediates in the protozoan parasite Leishmania. Free Radic Biol Med46:367–375
112. Morgan HP, McNae IW, Hsin K Y, Michels PA, Fothergill-Gilmore LA, Walkinshaw MD (2010) An improved strategy for the crystallization of Leishmania mexicana pyruvate kinase. Acta Crystallogr Sect F Struct Biol Cryst Commun 66:215–218
113. Morgan HP, Walsh MJ, Blackburn EA, Wear MA, Boxer MB, Shen M, Veith H, McNae IW, Nowicki MW, Michels PA, Auld DS, Fothergill-Gilmore LA, Walkinshaw MD (2012) A new family of covalent inhibitors block nucleotide binding to the active site of pyruvate kinase.Biochem J 448:62–72
114. Morris MT, DeBruin C, Yang Z, Chambers JW, Smith KS, Morris JC (2006) Activity of a second Trypanosoma brucei hexokinase is controlled by an 18-amino-acid C-terminal tail. Eukaryot Cell 5:2014–2023
115. Mpamhanga CP, Spinks D, Tulloch LB, Shanks EJ, Robinson DA, Collie IT, Fairlamb AH, Wyatt PG, Frearson JA, Hunter WN, Gilbert IH, Brenk R (2009) One scaffold, three binding modes: novel and selective pteridine reductase 1 inhibitors derived from fragment hits discovered by virtual screening. J Med Chem 52:4454–4465
116. Myler PJ (2008) Searching the Tritryp genomes for drug targets. Adv Exp Med Biol625:133–140
117. Nare B, Garraway LA, Vickers TJ, Beverley SM (2009) PTR1-dependent synthesis of tetrahydro-biopterin contributes to oxidant susceptibility in the trypanosomatid protozoan parasite Leishmania major. Curr Genet 55:287–299
118. Nare B, Hardy LW, Beverley SM (1997) The roles of pteridine reductase 1 and dihydrofolate reductase-thymidylate synthase in pteridine metabolism in the protozoan parasite Leishmania major. J Biol Chem 272:13883–13891
119. Naula C, Parsons M, Mottram JC (2005) Protein kinases as drug targets in trypanosomes and Leishmania. Biochim Biophys Acta 1754:151–159
120. Neal RA, Croft SL (1984) An in-vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani. J Antimicrob Chemother14:463–475
121. Nenortas E, Burri C, Shapiro TA (1999) Antitrypanosomal activity of fl uoroquinolones. Antimicrob Agents Chemother 43:2066–2068
122. Nenortas E, Kulikowicz T, Burri C, Shapiro TA (2003) Antitrypanosomal activities of fl uoroquino-lones with pyrrolidinyl substitutions. Antimicrob Agents Chemother 47:3015–3017
123. Nowicki MW, Tulloch LB, Worralll L, McNae IW, Hannaert V, Michels PA, Fothergill-Gilmore LA, Walkinshaw MD, Turner NJ (2008) Design, synthesis and trypanocidal activity of lead compounds based on inhibitors of parasite glycolysis. Bioorg Med Chem 16:5050–5061
124. Nussbaum K, Honek J, Cadmus CM, Efferth T (2010) Trypanosomatid parasites causing neglected diseases. Curr Med Chem 17:1594–1617
125. O’Brien TC, Mackey ZB, Fetter RD, Choe Y, O’Donoghue AJ, Zhou M, Craik CS, Caffrey CR, McKerrow JH (2008) A parasite cysteine protease is key to host protein degradation and iron acquisition. J Biol Chem 283:28934–28943
126. Oduor RO, Ojo KK, Williams GP, Bertelli F, Mills J, Maes L, Pryde DC, Parkinson T, Van Voorhis WC, Holler TP (2011) Trypanosoma brucei glycogen synthase kinase-3, a target for anti-trypanosomal drug development: a public-private partnership to identify novel leads. PLoS Negl Trop Dis 5:e1017
127. Ojo KK, Arakaki TL, Napuli AJ, Inampudi KK, Keyloun KR, Zhang L, Hol WG, Verlinde CL, Merritt EA, Van Voorhis WC (2011) Structure determination of glycogen synthase kinase-3 from Leishmania major and comparative inhibitor structure-activity relationships with Trypanosoma brucei GSK-3. Mol Biochem Parasitol 176:98–108
128. Ojo KK, Gillespie JR, Riechers AJ, Napuli AJ, Verlinde CL, Buckner FS, Gelb MH, Domostoj MM, Wells SJ, Scheer A, Wells TN, Van Voorhis WC (2008) Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. Antimicrob Agents Chemother 52:3710–3717
129. Olivares-Illana V, Perez-Montfort R, Lopez-Calahorra F, Costas M, Rodriguez-Romero A, Tuena de GomezPuyou M, Gomez Puyou A (2006) Structural differences in triosephosphate isomerase from different species and discovery of a multitrypanosomatid inhibitor. Biochemistry 45:2556–2560
130. Olivares-Illana V, Rodríguez-Romero A, Becker I, Berzunza M, García J, Pérez-Montfort R, Cabrera N, López-Calahorra F, de Gómez-Puyou MT, Gómez-Puyou A (2007) Perturbation of the dimer interface of triosephosphate isomerase and its effect on Trypanosoma cruzi. PLoS Negl Trop Dis 1(1):e01
131. Orenes Lorente S, Gomez R, Jimenez C, Cammerer S, Yardley V, de Luca-Fradley K, Croft SL, Ruiz Perez LM, Urbina J, Gonzalez Pacanowska D, Gilbert IH (2005) Biphenylquinuclidines as inhibitors of squalene synthase and growth of parasitic protozoa. Bioorg Med Chem 13:3519–3529
132. Padhy BM, Gupta YK (2011) Drug repositioning: re-investigating existing drugs for new therapeutic indications. J Postgrad Med 57:153–160
133. Phukan S, Babu VS, Kannoji A, Hariharan R, Balaji VN (2010) GSK3beta: role in therapeutic landscape and development of modulators. Br J Pharmacol 160:1–19
134. Polychronopoulos P, Magiatis P, Skaltsounis AL, Myrianthopoulos V, Mikros E, Tarricone A, Musacchio A, Roe SM, Pearl L, Leost M, Greengard P, Meijer L (2004) Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem 47:935–946
135. Racagni GE, Machado de Domenech EE (1983) Characterization of Trypanosoma cruzi hexokinase. Mol Biochem Parasitol 9:181–188
136. Robays J, Nyamowala G, Sese C, BetuKu Mesu Kande V, Lutumba P, Van der Veken W, Boelaert M (2008) High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo. Emerg Infect Dis 14:966–967
137. Robertson SA, Renslo AR (2011) Drug discovery for neglected tropical diseases at the Sandler Center. Future Med Chem 3:1279–1288
138. Rodrigues-Poveda CA, Gonzalez-Pacanowska D, Szajnman SH, Rodriguez JB (2012) 2-Alkylaminoethyl-1,1-Bisphosphonic acids are potent inhibitors of the enzymatic activity of Trypanosoma cruzi squalene synthase. Antimicrob Agents Chemother 56:4483–4486
139. Rodrigues JC, Attias M, Rodriguez C, Urbina JA, Souza W (2002) Ultrastructural and biochemical alterations induced by 22,26-azasterol, a delta(24(25))-sterol methyltransferase inhibitor, on promastigote and amastigote forms of Leishmania amazonensis. Antimicrob Agents Chemother 46:487–499
140. Romeiro NC, Aguirre G, Hernandez P, Gonzalez M, Cerecetto H, Aldana I, Perez-Silanes S, Monge A, Barreiro EJ, Lima LM (2009) Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates. Bioorg Med Chem 17:641–652
141. Rottenberg ME, Masocha W, Ferella M, Petitto-Assis F, Goto H, Kristensson K, McCaffrey R, Wigzell H (2005) Treatment of African trypanosomiasis with cordycepin and adenosine deaminase inhibitors in a mouse model. J Infect Dis 192:1658–1665
142. Salem MM, Werbovetz KA (2005) Antiprotozoal compounds from Psorothamnus polydenius.J Nat Prod 68:108–111
143. Sanz-Rodriguez CE, Concepcion JL, Pekerar S, Oldfi eld E, Urbina JA (2007) Bisphosphonates as inhibitors of Trypanosoma cruzi hexokinase: kinetic and metabolic studies. J Biol Chem282:12377–12387
144. Schurigt U, Schad C, Glowa C, Baum U, Thomale K, Schnitzer JK, Schultheis M, Schaschke N, Schirmeister T, Moll H (2010) Aziridine-2,3-dicarboxylate-based cysteine cathepsin inhibitors induce cell death in Leishmania major associated with accumulation of debris in autophagy-related lysosome-like vacuoles. Antimicrob Agents Chemother 54:5028–5041
145. Sealey-Cardona M, Cammerer S, Jones S, Ruiz-Perez LM, Brun R, Gilbert IH, Urbina JA, Gonzalez-Pacanowska D (2007) Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives. Antimicrob Agents Chemother 51:2123–2129
146. Sett R, Basu N, Ghosh AK, Das PK (1992) Potential of doxorubicin as an antileishmanial agent.J Parasitol 78:350–354
147. Sienkiewicz N, Jaroslawski S, Wyllie S, Fairlamb AH (2008) Chemical and genetic validation of dihydrofolate reductase-thymidylate synthase as a drug target in African trypanosomes. Mol Microbiol 69:520–533
148. Singh G, Dey CS (2007) Induction of apoptosis-like cell death by pentamidine and doxorubicin through differential inhibition of topoisomerase II in arsenite-resistant L. donovani. Acta Trop103:172–185
149. Singh N, Kumar M, Singh RK (2012) Leishmaniasis: current status of available drugs and new potential drug targets. Asian Pac J Trop Med 5:485–497
150. Smirlis D, Duszenko M, Ruiz AJ, Scoulica E, Bastien P, Fasel N, Soteriadou K (2010) Targeting essential pathways in trypanosomatids gives insights into protozoan mechanisms of cell death.Parasit Vectors 3:107
151. Smirlis D, Soteriadou K (2011) Trypanosomatid apoptosis: ‘apoptosis’ without the canonical regulators. Virulence 2:253–256
152. Souza DH, Garratt RC, Araujo AP, Guimaraes BG, Jesus WD, Michels PA, Hannaert V, Oliva G (1998) Trypanosoma cruzi glycosomal glyceraldehyde-3-phosphate dehydrogenase: structure, catalytic mechanism and targeted inhibitor design. FEBS Lett 424:131–135
153. Steverding D, Wang X (2009) Evaluation of anti-sleeping-sickness drugs and topoisomerase inhibitors in combination on Trypanosoma brucei. J Antimicrob Chemother 63:1293–1295
154. Strauss PR, Wang JC (1990) The TOP2 gene of Trypanosoma brucei: a single-copy gene that shares extensive homology with other TOP2 genes encoding eukaryotic DNA topoisomeraseII. Mol Biochem Parasitol 38:141–150
155. Suckling KE (2006) The return of two old targets? Expert Opin Ther Targets 10:785–788
156. Suresh S, Bressi JC, Kennedy KJ, Verlinde CL, Gelb MH, Hol WG (2001) Conformational changes in Leishmania mexicana glyceraldehyde-3-phosphate dehydrogenase induced by designed inhibitors. J Mol Biol 309:423–435
157. Teixeira SM, de Paiva RM, Kangussu-Marcolino MM, Darocha WD (2012) Trypanosomatid comparative genomics: contributions to the study of parasite biology and different parasitic diseases. Genet Mol Biol 35:1–17
158. Torrie LS, Wyllie S, Spinks D, Oza SL, Thompson S, Harrison JR, Gilbert IH, Wyatt PG, Fairlamb AH, Frearson JA (2009) Chemical validation of trypanothione synthetase: a potential drug target for human trypanosomiasis. J Biol Chem 284:36137–36145
159. Tu X, Wang CC (2004) The involvement of two cdc2-related kinases (CRKs) in Trypanosoma brucei cell cycle regulation and the distinctive stage-specifi c phenotypes caused by CRK3 depletion. J Biol Chem 279:20519–20528
160. Tulloch LB, Morgan HP, Hannaert V, Michels PA, Fothergill-Gilmore LA, Walkinshaw MD (2008) Sulphate removal induces a major conformational change in Leishmania mexicana pyruvate kinase in the crystalline state. J Mol Biol 383:615–626
161. Urbina JA (2002) Chemotherapy of Chagas disease. Curr Pharm Des 8:287–295
162. Urbina JA (2010) Specifi c chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 115:55–68
163. Urbina JA, Concepcion JL, Caldera A, Payares G, Sanoja C, Otomo T, Hiyoshi H (2004) In vitro and in vivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi. Antimicrob Agents Chemother 48:2379–2387
164. Urbina JA, Concepcion JL, Montalvetti A, Rodriguez JB, Docampo R (2003) Mechanism of action of 4-phenoxyphenoxyethyl thiocyanate (WC-9) against Trypanosoma cruzi, the causative agent of Chagas’ disease. Antimicrob Agents Chemother 47:2047–2050
165. Urbina JA, Concepcion JL, Rangel S, Visbal G, Lira R (2002) Squalene synthase as a chemotherapeu-tic target in Trypanosoma cruzi and Leishmania mexicana. Mol Biochem Parasitol 125:35–45
166. Urbina JA, Crespo A (1984) Regulation of energy metabolism in Trypanosoma (Schizotrypanum) cruzi epimastigotes. I. Hexokinase and phosphofructokinase. Mol Biochem Parasitol11:225–239
167. Urbina JA, Docampo R (2003) Specifi c chemotherapy of Chagas disease: controversies and advances. Trends Parasitol 19:495–501
168. Urbina JA, Lazardi K, Aguirre T, Piras MM, Piras R (1988) Antiproliferative synergism of the allylamine SF 86-327 and ketoconazole on epimastigotes and amastigotes of Trypanosoma(Schizotrypanum) cruzi. Antimicrob Agents Chemother 32:1237–1242
169. Urbina JA, Payares G, Molina J, Sanoja C, Liendo A, Lazardi K, Piras MM, Piras R, Perez N, Wincker P, Ryley JF (1996a) Cure of short- and long-term experimental Chagas’ disease using D0870. Science 273:969–971
170. Urbina JA, Vivas J, Lazardi K, Molina J, Payares G, Piras MM, Piras R (1996b) Antiproliferative effects of delta 24(25) sterol methyl transferase inhibitors on Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Chemotherapy 42:294–307
171. Urbina JA, Vivas J, Visbal G, Contreras LM (1995) Modifi cation of the sterol composition of Trypanosoma (Schizotrypanum) cruzi epimastigotes by delta 24(25)-sterol methyl transferase inhibitors and their combinations with ketoconazole. Mol Biochem Parasitol 73:199–210
172. Van Hellemond JJ, Neuville P, Schwarz RT, Matthews KR, Mottram JC (2000) Isolation of Trypanosoma brucei CYC2 and CYC3 cyclin genes by rescue of a yeast G(1) cyclin mutant. Functional characterization of CYC2. J Biol Chem 275:8315–8323
173. Vannier-Santos MA, Urbina JA, Martiny A, Neves A, de Souza W (1995) Alterations induced by the antifungal compounds ketoconazole and terbinafi ne in Leishmania. J Eukaryot Microbiol42:337–346
174. Vellieux FM, Hajdu J, Verlinde CL, Groendijk H, Read RJ, Greenhough TJ, Campbell JW, Kalk KH, Littlechild JA, Watson HC et al (1993) Structure of glycosomal glyceraldehyde-3-phosphate dehydrogenase from Trypanosoma brucei determined from Laue data. Proc Natl Acad Sci USA 90:2355–2359
175. Verlinde CL, Hannaert V, Blonski C, Willson M, Perie JJ, Fothergill-Gilmore LA, Opperdoes FR, Gelb MH, Hol WG, Michels PA (2001) Glycolysis as a target for the design of new anti- trypanosome drugs. Drug Resist Updat 4:50–65
176. Walker RG, Thomson G, Malone K, Nowicki MW, Brown E, Blake DG, Turner NJ, Walkinshaw MD, Grant KM, Mottram JC (2011) High throughput screens yield small molecule inhibitors of Leishmania CRK3: CYC6 cyclin-dependent kinase. PLoS Negl Trop Dis 5:e1033
177. Wang Q, Melzer IM, Kruse M, Sander-Juelch C, Wiese M (2005) LmxMPK4, a mitogen-activated protein (MAP) kinase homologue essential for promastigotes and amastigotes of Leishmania mexicana. Kinetoplastid Biol Dis 4:6
178. Wang Y, Dimitrov K, Garrity LK, Sazer S, Beverley SM (1998) Stage-specifi c activity of the Leishmania major CRK3 kinase and functional rescue of a Schizosaccharomyces pombe cdc2 mutant. Mol Biochem Parasitol 96:139–150
179. Wierenga RK, Noble ME, Postma JP, Groendijk H, Kalk KH, Hol WG, Opperdoes FR (1991a) The crystal structure of the “open” and the “closed” conformation of the fl exible loop of trypano-somal triosephosphate isomerase. Proteins 10:33–49
180. Wierenga RK, Noble ME, Vriend G, Nauche S, Hol WG (1991b) Refi ned 1.83 a structure of trypanosomal triosephosphate isomerase crystallized in the presence of 2.4 M-ammonium sulphate. A comparison with the structure of the trypanosomal triosephosphate isomerase-glycerol-3-phosphate complex. J Mol Biol 220:995–1015
181. Wiese M (1998) A mitogen-activated protein (MAP) kinase homologue of Leishmania mexicana is essential for parasite survival in the infected host. EMBO J 17:2619–2628
182. Wiese M (2007) Leishmania MAP kinases–familiar proteins in an unusual context. Int J Parasitol 37:1053–1062
183. Williams JC, Zeelen JP, Neubauer G, Vriend G, Backmann J, Michels PA, Lambeir AM, Wierenga RK (1999) Structural and mutagenesis studies of leishmania triosephosphate isomerase: a point mutation can convert a mesophilic enzyme into a superstable enzyme without losing catalytic power. Protein Eng 12:243–250
184. Williamson J, Scott-Finnigan TJ (1978) Trypanocidal activity of antitumor antibiotics and other metabolic inhibitors. Antimicrob Agents Chemother 13:735–744
185. Willson M, Lauth N, Perie J, Callens M, Opperdoes FR (1994) Inhibition of glyceraldehyde-3-phosphate dehydrogenase by phosphorylated epoxides and alpha-enones. Biochemistry 33:214–220
186. Xingi E, Smirlis D, Myrianthopoulos V, Magiatis P, Grant KM, Meijer L, Mikros E, Skaltsounis AL, Soteriadou K (2009) 6-Br-5methylindirubin-3′oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasis. Int J Parasitol 39:1289–1303
187. Zhu F, Han B, Kumar P, Liu X, Ma X, Wei X, Huang L, Guo Y, Han L, Zheng C, Chen Y (2010) Update of TTD: therapeutic target database. Nucleic Acids Res 38:D787–791